Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "drug interactions" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-2 z 2
    Tytuł:
    Safety of oral nifuroxazide – analysis of data from a spontaneous reporting system
    Autorzy:
    Karlowicz-Bodalska, Katarzyna
    Głowacka, Krystyna
    Boszkiewicz, Kamila
    Han, Stanisław
    Wiela-Hojeńska, Anna
    Powiązania:
    https://bibliotekanauki.pl/articles/895655.pdf
    Data publikacji:
    2019-08-30
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    diarrhea
    gastrointestinal tract
    pharmacovigilance
    drug interactions
    nifuroxazide
    Opis:
    Nifuroxazide is a popular chemotherapeutic agent, that is widely used in Poland in acute and chronic bacterial diarrhea treatment. It is available in pharmacies as over-the-counter tablets for adults and a suspension on prescription for children. The aim of the study was to assess the safety of nifuroxazide therapy. Adverse reaction reports from the Regional Pharmacovigilance Center in Wroclaw, the pharmaceutical company PPF Hasco-Lek, and VigiAccess and EudraVigilance databases were analyzed. Based on the analysis of the data collected from the above sources, nifuroxazide have shown a high therapeutic value in the gastrointestinal tract infections, maintaining high safety of usage at the same time. The number of drug application adverse reactions in Poland is not so high primarily due to high safety profile and low patient awareness of the possibility of reporting drug side effects.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 4; 745-751
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    In Vitro approach for identification of a leading cytochrome P450 isoenzyme responsible for biotransformation of novel arylpiperazine drug candidates and their inhibition potency towards CYP3A4.
    Autorzy:
    Ulenberg, Szymon
    Belka, Mariusz
    Georgiev, Paweł
    Król, Marek
    Herold, Franciszek
    Bączek, Tomasz
    Powiązania:
    https://bibliotekanauki.pl/articles/895671.pdf
    Data publikacji:
    2020-02-29
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    cytochrome P-450
    drug-drug interactions
    isoform
    arylpiperazine
    CYP 3A4 inhibitor
    metabolic stability
    Opis:
    Presented article is a follow-up study of previous work, published in PLoS ONE in 2015 regarding metabolic stability of arylpiperazine derivatives, a very promising group of novel antidepressants. The aim of this study was to identify cytochrome P450 (CYP) isoforms that participate in the metabolism of some novel arylpiperazine derivatives developed by authors as well as their potency to inhibit reactions catalysed by identified lead metabolizing enzyme. Such studies allow to predict possible drug-drug interactions that might occur during co-administration of studied compounds with other drugs that are metabolized by identified enzyme. The compounds were incubated in vitro together with the isolated CYP isoforms. After the incubation, samples were analyzed by liquid chromatography coupled with mass spectrometry. The results showed main contribution of CYP3A4 isoform in biotransformation of the investigated derivatives. With CYP3A4 being the main CYP isoform responsible for the metabolism of arylpiperazine derivatives and at the same time being the main metabolizing enzyme for almost 50% of all drugs, a high chance of in vivo drug-drug interactions emerged. Therefore, IC50 values were also determined using testosterone hydroxylation as a probe reaction, specific for CYP3A4. The resulting values ranged from 6.13 to 15.85 µM, which places studied derivatives as moderate or weak inhibitors of CYP3A4. Those results, combined with conclusion that all of the arylpiperazine derivatives are also metabolized to some extent by other CYP isoforms (providing alternative metabolic pathways), result in conclusion that studied arylpiperazines might be safe for co-administration with other CYP3A4 substrates.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2020, 77, 1; 69-76
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-2 z 2

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies